Executive summary Liver diseases have become a major health threat across Europe, and
the face of European hepatology is changing due to the cure of viral hepatitis C and the …

Background & Aims Accurate estimates for the contemporary burden of chronic liver disease
(CLD) are vital for setting clinical, research, and policy priorities. We aimed to review the …

Background Despite the goal set by WHO to eliminate hepatitis C virus (HCV) as a public
health threat, uptake of HCV testing and treatment remains low. To achieve this target …

Nonalcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease. A
single‐nucleotide polymorphism (SNP), rs6834314, was associated with serum liver …

Background There are concerns around poorer response to direct-acting antiviral (DAA)
therapy for hepatitis C virus infection among people who use drugs. This systematic review …

Background Despite revised guidelines that no longer exclude people who inject drugs
(PWID) from treatment for hepatitis C virus (HCV) infection, many clinicians are reluctant to …

Background & Aims HCV reinfection following successful treatment can compromise
treatment outcomes. This systematic review assessed the rate of HCV reinfection following …

Viral hepatitis is a major public health threat and a leading cause of death worldwide.
Annual mortality from viral hepatitis is similar to that of other major infectious diseases such …

Abstract Background To achieve the World Health Organization hepatitis C virus (HCV)
elimination targets, it is essential to increase access to direct-acting antivirals (DAAs) …

Globally, some 71 million people are chronically infected with hepatitis C virus (HCV).
Marginalized populations, particularly people who inject drugs (PWID), have low testing …